Division of Hematology/Oncology

Faculty

faculty photo

Edward A. Stadtmauer, MD

Professor of Medicine at the Hospital of the University of Pennsylvania
Co-Leader, Hematologic Malignancies Program, University of Pennsylvania Abramson Cancer Center
Co-Leader, Hematologic Malignancies Translational Center of Excellence, Penn Medicine/Abramson Cancer Center
Chief, Section of Hematologic Malignancies, Division of Hematology-Oncology, Department of Medicine
Department: Medicine

Contact information
2 Perelman Center for Advanced Medicine
34th and Civic Center Bld
2-319S
Philadelphia, PA 19104
Office: 2156627910
Fax: 215-662-4064
Education:
A.B. (Biochemistry)
Cornell University, College of Arts and Sciences, 1979.
M.D. (Medicine)
University of Pennsylvania School of Medicine, 1983.
Post-Graduate Training
Intern, Internal Medicine, Bronx Muncipal Hospital, Albert Einstein College of Medicine, Bronx, NY, 1983-1984.
Resident, Internal Medicine, Bronx Muncipal Hospital, Albert Einstein College of Medicine, Bronx, NY, 1984-1986.
Fellowship, Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, 1986-1989.
Certifications
Internal Medicine, 1986.
Hematology, 1988.
Medical Oncology, 1989.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical trials, Bone Marrow Transplant

Description of Clinical Expertise

Myeloma, Leukemia, Lymphoma and Bone Marrow and Stem Cell Transplant

Selected Publications

Rapoport Aaron P, Aqui Nicole A, Stadtmauer Edward A, Vogl Dan T, Xu Yin Yan, Kalos Michael, Cai Ling, Fang Hong-Bin, Weiss Brendan M, Badros Ashraf, Yanovich Saul, Akpek Gorgun, Tsao Patricia, Cross Alan, Mann Dean, Philip Sunita, Kerr Naseem, Brennan Andrea, Zheng Zhaohui, Ruehle Kathleen, Milliron Todd, Strome Scott E, Salazar Andres M, Levine Bruce L, June Carl H: Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20(5): 1355-65, Mar 2014.

Chng W J, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel J S, Sonneveld P, Cavo M, Usmani S, Durie B G M, Avet-Loiseau H: IMWG consensus on risk stratification in multiple myeloma. Leukemia 28(2): 269-77, Feb 2014.

Mulligan George, Lichter David I, Di Bacco Alessandra, Blakemore Stephen J, Berger Allison, Koenig Erik, Bernard Hugues, Trepicchio William, Li Bin, Neuwirth Rachel, Chattopadhyay Nibedita, Bolen Joseph B, Dorner Andrew J, van de Velde Helgi, Ricci Deborah, Jagannath Sundar, Berenson James R, Richardson Paul G, Stadtmauer Edward A, Orlowski Robert Z, Lonial Sagar, Anderson Kenneth C, Sonneveld Pieter, San Miguel Jesús F, Esseltine Dixie-Lee, Schu Matthew: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood 123(5): 632-9, Jan 2014.

Micallef Ivana N, Stiff Patrick J, Stadtmauer Edward A, Bolwell Brian J, Nademanee Auayporn P, Maziarz Richard T, Partisano Angela M, Marulkar Sachin, DiPersio John F: Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. American journal of hematology 88(12): 1017-23, Dec 2013.

Jakubowiak A J, Siegel D S, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu F J, Somlo G, Zonder J, Song K, Stewart A K, Stadtmauer E, Harrison B L, Wong A F, Orlowski R Z, Jagannath S: Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia 27(12): 2351-6, Dec 2013.

Kaufman Jonathan L, Niesvizky Ruben, Stadtmauer Edward A, Chanan-Khan Asher, Siegel David, Horne Heather, Wegener William A, Goldenberg David M: Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. British journal of haematology 163(4): 478-86, Nov 2013.

Nagle Sarah J, Woo Kaitlin, Schuster Stephen J, Nasta Sunita D, Stadtmauer Edward, Mick Rosemarie, Svoboda Jakub: Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. American journal of hematology 88(10): 890-4, Oct 2013.

Linette, Gerald P. Stadtmauer, Edward A. Maus, Marcela V. Rapoport, Aaron P. Levine, Bruce L. Emery, Lyndsey. Litzky, Leslie. Bagg, Adam. Carreno, Beatriz M. Cimino, Patrick J. Binder-Scholl, Gwendolyn K. Smethurst, Dominic P. Gerry, Andrew B. Pumphrey, Nick J. Bennett, Alan D. Brewer, Joanna E. Dukes, Joseph. Harper, Jane. Tayton-Martin, Helen K. Jakobsen, Bent K. Hassan, Namir J. Kalos, Michael. June, Carl H.: Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6): 863-71, Aug 8 2013.

Cameron Brian J, Gerry Andrew B, Dukes Joseph, Harper Jane V, Kannan Vivekanandan, Bianchi Frayne C, Grand Francis, Brewer Joanna E, Gupta Minnal, Plesa Gabriela, Bossi Giovanna, Vuidepot Annelise, Powlesland Alex S, Legg Alison, Adams Katherine J, Bennett Alan D, Pumphrey Nicholas J, Williams Daniel D, Binder-Scholl Gwendolyn, Kulikovskaya Irina, Levine Bruce L, Riley James L, Varela-Rohena Angel, Stadtmauer Edward A, Rapoport Aaron P, Linette Gerald P, June Carl H, Hassan Namir J, Kalos Michael, Jakobsen Bent K: Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science translational medicine 5(197): 197ra103, Aug 2013.

Landsburg, Daniel J. Stadtmauer, Edward. Loren, Alison. Goldstein, Steven. Frey, Noelle. Nasta, Sunita D. Porter, David L. Tsai, Donald E. Perl, Alexander E. Hexner, Elizabeth O. Luger, Selina.: Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American Journal of Hematology 88(8): 657-60, Aug 2013.

back to top
Last updated: 11/06/2014
The Trustees of the University of Pennsylvania
 

Clinical Briefings Blog Spot

Penn MD Forum title with Penn Medicine Shield and Twitter